142
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14)

, , , , , & show all
Pages 1-12 | Received 06 Sep 2023, Accepted 12 Dec 2023, Published online: 11 Jan 2024

References

  • Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol. 2014;9(1):12–20. doi:10.2215/CJN.02730313
  • Pavkov HJ, Burrows NR, Trends in Hospitalizations for Acute Kidney Injury - United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2018;67:289–293. doi:10.15585/mmwr.mm6710a2
  • Sawhney S, Marks A, Fluck N, Levin A, Prescott G, Black C. Intermediate and Long-term Outcomes of Survivors of Acute Kidney Injury Episodes: a Large Population-Based Cohort Study. Am J Kidney Dis. 2017;69(1):18–28. doi:10.1053/j.ajkd.2016.05.018
  • Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8(9):1482–1493. doi:10.2215/CJN.00710113
  • International Society of Nephrology. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Injury. Kidney Int. Suppl. Web site. Available from: https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf. Accessed January 8, 2024.
  • Koyner JL, Mackey RH, Rosenthal NA, et al. Clinical outcomes of persistent severe acute kidney injury among patients with KDIGO stage 2 or 3 AKI. Am J Nephrol. 2022;53(11–12):816–825. doi:10.1159/000528158
  • Mehta S, Chauhan K, Patel A, et al. The prognostic importance of duration of AKI: a systematic review and meta-analysis. BMC Nephrol. 2018;19(1):91. doi:10.1186/s12882-018-0876-7
  • Rewa O, Bagshaw SM. Acute kidney injury—epidemiology, outcomes and economics. Nat Rev Nephrol. 2014;10(4):193–207. doi:10.1038/nrneph.2013.282
  • Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project: number of Discharges, United States, 2000 to 2020; 2022. Available from: http://datatools.ahrq.gov/hcupnet?type=subtab&tab=hcnis&count=11. Accessed December 21, 2022.
  • Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J. Acute kidney injury. Nature Reviews Disease Primers. 2021;7(1):52. doi:10.1038/s41572-021-00284-z
  • Kellum JA. Diagnostic Criteria for Acute Kidney Injury: present and Future. Crit Care Clin. 2015;31(4):621–632. doi:10.1016/j.ccc.2015.06.001
  • Moledina DG, Belliveau O, Yamamoto Y, et al. Variation in Best Practice Measures in Patients With Severe Hospital-Acquired Acute Kidney Injury: a Multicenter Study. Am J Kidney Dis. 2021;77(4):547–549. doi:10.1053/j.ajkd.2020.08.013
  • Küllmar M, Weiß R, Ostermann M, et al. A Multinational Observational Study Exploring Adherence With the Kidney Disease: improving Global Outcomes Recommendations for Prevention of Acute Kidney Injury After Cardiac Surgery. Anesth Analg. 2020;130(4):910–916. doi:10.1213/ANE.0000000000004642
  • Vaara ST, Bhatraju PK, Stanski NL, et al. Subphenotypes in acute kidney injury: a narrative review. Critical Care. 2022;26(1):251. doi:10.1186/s13054-022-04121-x
  • Hoste E, Bihorac A, Al-Khafaji A, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med. 2020;46(5):943–953. doi:10.1007/s00134-019-05919-0
  • Koyner JL, Mackey RH, Rosenthal NA, et al. Healthcare resource utilization and costs of persistent severe AKI among hospitalized Stage 2/3 AKI patients. Kidney360. 2022.
  • Koyner JL, Chawla LS, Bihorac A, et al. Performance of a Standardized Clinical Assay for Urinary C-C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury. Kidney360. 2022;3(7):1158–1168. doi:10.34067/KID.0008002021
  • Microsoft Excel for Microsoft 365, [computer program]. Version Version 2304 Build 16.0.16327.20200 - 64 bit2022.
  • Brazzelli M, Aucott L, Aceves-Martins M, et al. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2022;26(7):1–286. doi:10.3310/UGEZ4120
  • Hall PS, Mitchell ED, Smith AF, et al. The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation. Health Technol Assess. 2018;22(32):1–274. doi:10.3310/hta22320
  • ClinicalTrials.gov. Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery (PrevProgAKI) - NCT05275218. Available from: https://clinicaltrials.gov/ct2/show/NCT05275218. Accessed April 17, 2023.
  • Arias E, Xu J. United States Life Tables, 2020. National Vital Stat Rep. 2022;71:1–64.
  • United States Renal Data System. USRDS Annual Data Report: epidemiology of kidney disease in the United States. Available from: https://adr.usrds.org/2022. Accessed November 10, 2022.
  • CMS. Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-1768-F). Available from: https://www.cms.gov/newsroom/fact-sheets/calendar-year-2023-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1768-f. Accessed January 11, 2023.
  • ICER. 2020-2023 Value Assessment Framework. Available from: https://icer-review.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf. Accessed July 10, 2021.
  • Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford University Pres; 2006.
  • Jacobsen E, Sawhney S, Brazzelli M, et al. Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury. BMC Nephrol. 2021;22(1):399. doi:10.1186/s12882-021-02610-9
  • Kellum JA, Sileanu FE, Bihorac A, Hoste EA, Chawla LS. Recovery after Acute Kidney Injury. Am J Respir Crit Care Med. 2017;195(6):784–791. doi:10.1164/rccm.201604-0799OC
  • Zarbock A, Küllmar M, Ostermann M, et al. Prevention of Cardiac Surgery-Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: the PrevAKI-Multicenter Randomized Controlled Trial. Anesth Analg. 2021;133(2):292–302. doi:10.1213/ANE.0000000000005458